Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

NCT03245385 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsors decision

Conditions

Atopic Dermatitis

Interventions

DRUG: Treatment with Halobetasol propionate 0.05% topical spray

Sponsor

Sun Pharmaceutical Industries Limited

Collaborators

[object Object]